Power Law company profile

Rubius Therapeutics

Biotech & Life Sciences · Cambridge, United States · Founded 2013 · IPO 2018 Unicorn

← All companies

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Revenue

$13M

Latest reported FY

Investors

1 investor on Rubius Therapeutics's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series A 1 investor entered at this stage

Flagship Pioneering

Global footprint

Where Rubius Therapeutics has talent and traffic

Web traffic by country

2.8K monthly visits
across markets

🇦🇺 Australia100%

Top 1 markets shown

Patent intelligence

$1M patent portfolio · 11 active families

Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with topic prominence vs same-sector peers.

Estimated portfolio value

$1M

2236.2× smaller than top peer Illumina ($2.7B)

11 active patent families

Where Rubius Therapeutics innovates Erythroid cellMolecular biologyCell biologyCell systemBiochemistry

Tech-focus vs peers

Where Rubius Therapeutics concentrates inside the peer cluster

Axes are the most-shared Patsnap topics across Rubius Therapeutics and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).

Compare against

Top-topic prominence (rank inverted, 0–100)

Source: Dealroom Patent Intelligence · Patsnap top-10 topics per company

This is teaser data. The full per-sub-category breakdown, individual patent records, and quality-score history are on the Dealroom platform — request a demo to access.

See Rubius Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Open in Dealroom Book a demo